完整後設資料紀錄
DC 欄位語言
dc.contributor.authorChen, Feng-Chien_US
dc.date.accessioned2017-04-21T06:56:20Z-
dc.date.available2017-04-21T06:56:20Z-
dc.date.issued2017en_US
dc.identifier.issn1354-3776en_US
dc.identifier.urihttp://dx.doi.org/10.1080/13543776.2017.1301930en_US
dc.identifier.urihttp://hdl.handle.net/11536/133213-
dc.description.abstractIntroduction: Biotech patents are facing increasingly stern challenges. The patent statue holds that a multi-step method patent is not directly infringed unless all steps are carried out and attributed to a single entity. When separate steps are performed jointly by two or more parties, those parties are liable for divided infringement if there exists a direct infringement. Possibilities thus exist for unauthorized but non-infringing joint performance, i. e. enforcing a method patent will be difficult if joint performance stands as a valid defense against direct infringement. Areas covered: This analysis covers issues on patent infringement, specifically on divided infringement of diagnostic and method patents. Expert opinion: A retrospective analysis indicates that a large number of cancer diagnostic patents issued during 2005-2014 are potentially vulnerable to read on unauthorized use in the manner of joint performance. Inventors should draft patent claims appropriately to reduce the risk to assert their patents in this regard.en_US
dc.language.isoen_USen_US
dc.subjectCanceren_US
dc.subjectmethod patentsen_US
dc.subjectdiagnostic patentsen_US
dc.subjectdivided infringementen_US
dc.subjectpatent infringementen_US
dc.titleThe challenges of joint performance to method patentsen_US
dc.identifier.doi10.1080/13543776.2017.1301930en_US
dc.identifier.journalEXPERT OPINION ON THERAPEUTIC PATENTSen_US
dc.citation.volume27en_US
dc.citation.issue4en_US
dc.citation.spage393en_US
dc.citation.epage399en_US
dc.contributor.department生物科技學系zh_TW
dc.contributor.departmentDepartment of Biological Science and Technologyen_US
dc.identifier.wosnumberWOS:000396862600002en_US
顯示於類別:期刊論文